ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
出版年份 2016 全文链接
标题
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume 27, Issue 8, Pages 1386-1422
出版商
Oxford University Press (OUP)
发表日期
2016-07-06
DOI
10.1093/annonc/mdw235
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer
- (2016) Guy A. van Hazel et al. JOURNAL OF CLINICAL ONCOLOGY
- Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial
- (2015) A. Passardi et al. ANNALS OF ONCOLOGY
- Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest
- (2015) C. Cremolini et al. ANNALS OF ONCOLOGY
- Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial
- (2015) G. Masi et al. ANNALS OF ONCOLOGY
- BRAFcodons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis
- (2015) C. Cremolini et al. ANNALS OF ONCOLOGY
- Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)
- (2015) D. Koeberle et al. ANNALS OF ONCOLOGY
- A microRNA molecular modeling extension for prediction of colorectal cancer treatment
- (2015) Jian Li et al. BMC CANCER
- Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer
- (2015) Alexander Stein et al. BRITISH JOURNAL OF CANCER
- Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
- (2015) A Rowland et al. BRITISH JOURNAL OF CANCER
- Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis
- (2015) Robert C. G. Martin et al. CANCER
- Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer
- (2015) M. Peeters et al. CLINICAL CANCER RESEARCH
- SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer
- (2015) J. Randolph Hecht et al. Clinical Colorectal Cancer
- FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer
- (2015) C. Bokemeyer et al. EUROPEAN JOURNAL OF CANCER
- Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
- (2015) Filippo Pietrantonio et al. EUROPEAN JOURNAL OF CANCER
- A review of conventional and drug-eluting chemoembolization in the treatment of colorectal liver metastases: principles and proof
- (2015) David M Liu et al. Future Oncology
- Is it worth reorganising cancer services on the basis of multidisciplinary teams (MDTs)? A systematic review of the objectives and organisation of MDTs and their impact on patient outcomes
- (2015) Joan Prades et al. HEALTH POLICY
- Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
- (2015) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
- (2015) Ryan B. Corcoran et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment andRASMutations in Colorectal Cancer
- (2015) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
- (2015) Lieke H J Simkens et al. LANCET
- FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
- (2015) Chiara Cremolini et al. LANCET ONCOLOGY
- Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial
- (2015) Christophe Tournigand et al. LANCET ONCOLOGY
- Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial
- (2015) Susanna Hegewisch-Becker et al. LANCET ONCOLOGY
- Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data
- (2015) Didier Meulendijks et al. LANCET ONCOLOGY
- Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Jin Li et al. LANCET ONCOLOGY
- Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
- (2015) Josep Tabernero et al. LANCET ONCOLOGY
- The consensus molecular subtypes of colorectal cancer
- (2015) Justin Guinney et al. NATURE MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- (2015) David M. Hyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
- (2015) Robert J. Mayer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- External Quality Assessment Unravels Interlaboratory Differences in Quality of RAS Testing for Anti-EGFR Therapy in Colorectal Cancer
- (2015) V. Tack et al. ONCOLOGIST
- HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
- (2015) S. M. Kavuri et al. Cancer Discovery
- ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas
- (2015) A. Orlandi et al. Journal of Cancer
- Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H)
- (2014) J. Goldstein et al. ANNALS OF ONCOLOGY
- ExtendedRASmutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials
- (2014) M. J. Sorich et al. ANNALS OF ONCOLOGY
- Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
- (2014) K. M. Kerr et al. ANNALS OF ONCOLOGY
- Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial
- (2014) F. Ciardiello et al. ANNALS OF ONCOLOGY
- Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study)†
- (2014) G. Folprecht et al. ANNALS OF ONCOLOGY
- Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle
- (2014) L. De Mattos-Arruda et al. ANNALS OF ONCOLOGY
- Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis
- (2014) Y. Y. Juo et al. ANNALS OF ONCOLOGY
- Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
- (2014) J. Y. Douillard et al. ANNALS OF ONCOLOGY
- Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial
- (2014) T. Gruenberger et al. ANNALS OF ONCOLOGY
- Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013
- (2014) D. Papamichael et al. ANNALS OF ONCOLOGY
- The ERCC1 C118T Polymorphism Predicts Clinical Outcomes of Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy: a Meta-analysis Based on 22 Studies
- (2014) Ying-Ying Qian et al. Asian Pacific Journal of Cancer Prevention
- Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach
- (2014) Tiziana Comito et al. BMC CANCER
- Randomized multicentre trial of gadoxetic acid-enhanced MRIversusconventional MRI or CT in the staging of colorectal cancer liver metastases
- (2014) C. J. Zech et al. BRITISH JOURNAL OF SURGERY
- BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer
- (2014) Rona Yaeger et al. CANCER
- Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
- (2014) S. Venderbosch et al. CLINICAL CANCER RESEARCH
- Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin
- (2014) D. Elias et al. EJSO
- Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983
- (2014) E. Tanis et al. EUROPEAN JOURNAL OF CANCER
- Diagnostic accuracy and impact on management of 18F-FDG PET and PET/CT in colorectal liver metastasis: a meta-analysis and systematic review
- (2014) Anna Margherita Maffione et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Shifting sands: adapting the multidisciplinary team model to technological and organizational innovations in cancer care
- (2014) Joan Prades et al. Future Oncology
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Liquid Biopsies: Genotyping Circulating Tumor DNA
- (2014) Luis A. Diaz et al. JOURNAL OF CLINICAL ONCOLOGY
- PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
- (2014) Lee S. Schwartzberg et al. JOURNAL OF CLINICAL ONCOLOGY
- RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group
- (2014) Newton ACS Wong et al. JOURNAL OF CLINICAL PATHOLOGY
- The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery
- (2014) Arancha Prada-Villaverde et al. JOURNAL OF SURGICAL ONCOLOGY
- Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
- (2014) Timothy J Price et al. LANCET ONCOLOGY
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
- (2014) Volker Heinemann et al. LANCET ONCOLOGY
- Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial
- (2014) Harpreet Wasan et al. LANCET ONCOLOGY
- Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial
- (2014) John Primrose et al. LANCET ONCOLOGY
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
- (2014) Aaron M Newman et al. NATURE MEDICINE
- Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
- (2014) Alain R Thierry et al. NATURE MEDICINE
- Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
- (2014) Fotios Loupakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost Estimates and Economic Implications of Expanded RAS Testing in Metastatic Colorectal Cancer
- (2014) S. M. Kircher et al. ONCOLOGIST
- Combined Ablation and Resection (CARe) as an Effective Parenchymal Sparing Treatment for Extensive Colorectal Liver Metastases
- (2014) Serge Evrard et al. PLoS One
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- (2014) C. Bettegowda et al. Science Translational Medicine
- Stereotactic body radiotherapy for liver tumors
- (2014) Florian Sterzing et al. STRAHLENTHERAPIE UND ONKOLOGIE
- Decision-making in Colorectal Cancer Tumor Board meetings: Results of a prospective observational assessment
- (2014) S. Shah et al. SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
- Controversies in the oncosurgical management of liver limited stage IV colorectal cancer
- (2014) R.P. Jones et al. SURGICAL ONCOLOGY-OXFORD
- Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy
- (2014) S. Nöpel-Dünnebacke et al. ZEITSCHRIFT FUR GASTROENTEROLOGIE
- Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution
- (2014) S. Misale et al. Cancer Discovery
- Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing
- (2014) Sumitra Mohan et al. PLoS Genetics
- Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group
- (2013) W. Schmiegel et al. ANNALS OF ONCOLOGY
- A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial
- (2013) A. Johnsson et al. ANNALS OF ONCOLOGY
- Consensus Guidelines from The American Society of Peritoneal Surface Malignancies on Standardizing the Delivery of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Patients in the United States
- (2013) K. Turaga et al. ANNALS OF SURGICAL ONCOLOGY
- What to choose as radical local treatment for lung metastases from colo-rectal cancer: Surgery or radiofrequency ablation?
- (2013) Roel C.J. Schlijper et al. CANCER TREATMENT REVIEWS
- Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer
- (2013) M. Peeters et al. CLINICAL CANCER RESEARCH
- PIK3CA, BRAF , and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17
- (2013) Christos S. Karapetis et al. CLINICAL CANCER RESEARCH
- Multiplex Picodroplet Digital PCR to Detect KRAS Mutations in Circulating DNA from the Plasma of Colorectal Cancer Patients
- (2013) V. Taly et al. CLINICAL CHEMISTRY
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
- (2013) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial
- (2013) Josep Tabernero et al. EUROPEAN JOURNAL OF CANCER
- Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization
- (2013) Benjamin Garlipp et al. HEPATOLOGY
- KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy
- (2013) Emanuele Valtorta et al. INTERNATIONAL JOURNAL OF CANCER
- Is Stereotactic Body Radiation Therapy an Attractive Option for Unresectable Liver Metastases? A Preliminary Report From a Phase 2 Trial
- (2013) Marta Scorsetti et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients WithKRASWild-Type Unresectable Colorectal Liver-Limited Metastases
- (2013) Le-Chi Ye et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With Cetuximab
- (2013) Hubert Piessevaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer
- (2013) Catia Moutinho et al. JNCI-Journal of the National Cancer Institute
- Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial
- (2013) Bernard Nordlinger et al. LANCET ONCOLOGY
- Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
- (2013) David Cunningham et al. LANCET ONCOLOGY
- Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial
- (2013) Matthew T Seymour et al. LANCET ONCOLOGY
- FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials
- (2013) Giordano Domenico Beretta et al. MEDICAL ONCOLOGY
- Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
- (2013) Muhammed Murtaza et al. NATURE
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
- (2013) Sarah-Jane Dawson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology
- (2013) S Ogino et al. ONCOGENE
- PharmGKB summary
- (2013) Julia M. Barbarino et al. Pharmacogenetics and Genomics
- Rapid Two-Temperature Formalin Fixation
- (2013) David Chafin et al. PLoS One
- An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer
- (2013) Melanie Poulin-Costello et al. Targeted Oncology
- Outcomes of Single Fraction Stereotactic Ablative Radiotherapy for Lung Metastases
- (2013) Andrea R. Filippi et al. TECHNOLOGY IN CANCER RESEARCH & TREATMENT
- Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value
- (2013) Laetitia Marisa et al. PLOS MEDICINE
- Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004)
- (2012) T. Ruers et al. ANNALS OF ONCOLOGY
- ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
- (2012) H. J. Schmoll et al. ANNALS OF ONCOLOGY
- “Watchful waiting” for metastatic colorectal cancer, antediluvian or an option to be considered again?
- (2012) Timothy J PRICE et al. Asia-Pacific Journal of Clinical Oncology
- Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
- (2012) J Souglakos et al. BRITISH JOURNAL OF CANCER
- Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non-Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib
- (2012) E. A. Punnoose et al. CLINICAL CANCER RESEARCH
- Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood
- (2012) M. J. Higgins et al. CLINICAL CANCER RESEARCH
- Survival Differences in Patients With Metastatic Colorectal Cancer and With Single Site Metastatic Disease at Initial Presentation: Results From South Australian Clinical Registry for Advanced Colorectal Cancer
- (2012) Muhammad A. Khattak et al. Clinical Colorectal Cancer
- Treatment of Pulmonary Colorectal Metastases by Radiofrequency Ablation
- (2012) Elena N. Petre et al. Clinical Colorectal Cancer
- A combined oncogenic pathway signature ofBRAF,KRASandPI3KCAmutation improves colorectal cancer classification and cetuximab treatment prediction
- (2012) Sun Tian et al. GUT
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study
- (2012) Kjell Magne Tveit et al. JOURNAL OF CLINICAL ONCOLOGY
- Quantitative Assessment of Effect of Preanalytic Cold Ischemic Time on Protein Expression in Breast Cancer Tissues
- (2012) V. M. Neumeister et al. JNCI-Journal of the National Cancer Institute
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial
- (2012) Takayuki Yoshino et al. LANCET ONCOLOGY
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
- (2012) Jaafar Bennouna et al. LANCET ONCOLOGY
- Delay to formalin fixation ‘cold ischemia time’: effect on ERBB2 detection by in-situ hybridization and immunohistochemistry
- (2012) Bryce P Portier et al. MODERN PATHOLOGY
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
- (2012) Sandra Misale et al. NATURE
- The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
- (2012) Luis A. Diaz Jr et al. NATURE
- Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
- (2012) Clara Montagut et al. NATURE MEDICINE
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study
- (2012) E. Diaz-Rubio et al. ONCOLOGIST
- The Oncosurgery Approach to Managing Liver Metastases from Colorectal Cancer: A Multidisciplinary International Consensus
- (2012) R. Adam et al. ONCOLOGIST
- A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases
- (2012) Ingrid Fumagalli et al. Radiation Oncology
- Perkutane CT-gesteuerte Hochdosis-Brachytherapie (CT-HDRBT) von primären und metastatischen Lungentumoren in nicht chirurgischen Kandidaten
- (2012) F. Collettini et al. ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN
- Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA
- (2012) T. Forshew et al. Science Translational Medicine
- KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance
- (2012) J. R. Dijkstra et al. VIRCHOWS ARCHIV
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
- (2012) Ryan B. Corcoran et al. Cancer Discovery
- Complications After 1000 Lung Radiofrequency Ablation Sessions in 420 Patients: A Single Center’s Experiences
- (2011) Masataka Kashima et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Serial FDG–PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy
- (2011) A. Hendlisz et al. ANNALS OF ONCOLOGY
- A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection
- (2011) R. Wong et al. ANNALS OF ONCOLOGY
- Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
- (2011) C. Bokemeyer et al. ANNALS OF ONCOLOGY
- KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
- (2011) N Knijn et al. BRITISH JOURNAL OF CANCER
- Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
- (2011) Ben Tran et al. CANCER
- Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer
- (2011) Jeong Eun Kim et al. CANCER SCIENCE
- Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas
- (2011) K. Taniguchi et al. CLINICAL CANCER RESEARCH
- Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer
- (2011) Cecily P. Vaughn et al. GENES CHROMOSOMES & CANCER
- Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104—A Randomized Trial of the German AIO CRC Study Group
- (2011) Nicolas Moosmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Computed Tomography-Guided Interstitial High-Dose-Rate Brachytherapy in the Local Treatment of Primary and Secondary Intrathoracic Malignancies
- (2011) Nikolaos Tselis et al. Journal of Thoracic Oncology
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- (2011) Timothy S Maughan et al. LANCET
- Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- (2011) Richard A Adams et al. LANCET ONCOLOGY
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
- (2011) K. Yonesaka et al. Science Translational Medicine
- A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
- (2011) A. Bertotti et al. Cancer Discovery
- Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial
- (2010) R. Labianca et al. ANNALS OF ONCOLOGY
- Is Perioperative Chemotherapy Useful for Solitary, Metachronous, Colorectal Liver Metastases?
- (2010) Rene Adam et al. ANNALS OF SURGERY
- KRAS and BRAF Mutational Status in Primary Colorectal Tumors and Related Metastatic Sites: Biological and Clinical Implications
- (2010) Antoine Italiano et al. ANNALS OF SURGICAL ONCOLOGY
- Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial
- (2010) C Garufi et al. BRITISH JOURNAL OF CANCER
- Management of Peritoneal Carcinomatosis From Colorectal Cancer
- (2010) Eddy Cotte et al. CANCER JOURNAL
- Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
- (2010) S. E. Baldus et al. CLINICAL CANCER RESEARCH
- Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents
- (2010) J. E. Dancey et al. CLINICAL CANCER RESEARCH
- Dose-Escalation Study of Single-Fraction Stereotactic Body Radiotherapy for Liver Malignancies
- (2010) Karyn A. Goodman et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Local Response and Impact on Survival After Local Ablation of Liver Metastases From Colorectal Carcinoma by Computed Tomography–Guided High-Dose-Rate Brachytherapy
- (2010) Jens Ricke et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase III Trial Comparing Protracted Intravenous Fluorouracil Infusion Alone or With Yttrium-90 Resin Microspheres Radioembolization for Liver-Limited Metastatic Colorectal Cancer Refractory to Standard Chemotherapy
- (2010) Alain Hendlisz et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
- (2010) Marc Peeters et al. JOURNAL OF CLINICAL ONCOLOGY
- Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
- (2010) Niall C. Tebbutt et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
- (2010) Alberto Bardelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of Sanger Sequencing, Pyrosequencing, and Melting Curve Analysis for the Detection of KRAS Mutations
- (2010) Athanasios C. Tsiatis et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
- (2010) Gianluca Masi et al. LANCET ONCOLOGY
- The impact of pre-analytical processing on staining quality for H&E, dual hapten, dual color in situ hybridization and fluorescent in situ hybridization assays
- (2010) Andrea Babic et al. METHODS
- Detection ofKRASmutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach
- (2010) Pietro Carotenuto et al. PHARMACOGENOMICS
- Irinotecan pharmacogenomics
- (2010) Sharon Marsh et al. PHARMACOGENOMICS
- Characterisation of focal liver lesions undetermined at grey-scale US: contrast-enhanced US versus 64-row MDCT and MRI with liver-specific contrast agent
- (2010) T. V. Bartolotta et al. Radiologia Medica
- Diagnostic Imaging of Colorectal Liver Metastases with CT, MR Imaging, FDG PET, and/or FDG PET/CT: A Meta-Analysis of Prospective Studies Including Patients Who Have Not Previously Undergone Treatment
- (2010) Maarten Christian Niekel et al. RADIOLOGY
- The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer
- (2009) K. -L. Garm Spindler et al. ANNALS OF ONCOLOGY
- Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel
- (2009) B. Nordlinger et al. ANNALS OF ONCOLOGY
- Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
- (2009) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer
- (2009) N. Kemeny et al. ANNALS OF ONCOLOGY
- Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)
- (2009) H. Piessevaux et al. ANNALS OF ONCOLOGY
- A Systematic Review and Meta-Analysis of Cytoreductive Surgery with Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Origin
- (2009) Christopher Cao et al. ANNALS OF SURGICAL ONCOLOGY
- Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
- (2009) Astrid Lièvre et al. BMC CANCER
- Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial
- (2009) A Okines et al. BRITISH JOURNAL OF CANCER
- Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant
- (2009) F Molinari et al. BRITISH JOURNAL OF CANCER
- PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
- (2009) A. Sartore-Bianchi et al. CANCER RESEARCH
- PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer
- (2009) H. Prenen et al. CLINICAL CANCER RESEARCH
- Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases
- (2009) Yun Shin Chun JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue
- (2009) Jolien Tol et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study
- (2009) Benoist Chibaudel et al. JOURNAL OF CLINICAL ONCOLOGY
- PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
- (2009) Fotios Loupakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
- (2009) Pierre Laurent-Puig et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Individualized Stereotactic Body Radiotherapy of Liver Metastases
- (2009) Mark T. Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Liver Metastases
- (2009) Kyle E. Rusthoven et al. JOURNAL OF CLINICAL ONCOLOGY
- Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: A systematic review and meta-analysis
- (2009) Irene Floriani et al. JOURNAL OF MAGNETIC RESONANCE IMAGING
- Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
- (2009) Gunnar Folprecht et al. LANCET ONCOLOGY
- BRAFMutation in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study
- (2009) M. Kozloff et al. ONCOLOGIST
- KRAS Mutations in Primary Colorectal Cancer Tumors and Related Metastases: A Potential Role in Prediction of Lung Metastasis
- (2009) Paloma Cejas et al. PLoS One
- Microsatellite instability: a predictive marker in metastatic colorectal cancer?
- (2009) Gaëtan Des Guetz et al. Targeted Oncology
- PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
- (2008) F. Perrone et al. ANNALS OF ONCOLOGY
- PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab
- (2008) M. Jhawer et al. CANCER RESEARCH
- K-Ras Mutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive Fluoropyrimidine Therapy
- (2008) M.-C. Etienne-Grimaldi et al. CLINICAL CANCER RESEARCH
- Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group
- (2008) C. I. Müller et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Oxaliplatin Plus Irinotecan Compared With Irinotecan Alone as Second-Line Treatment After Single-Agent Fluoropyrimidine Therapy for Metastatic Colorectal Carcinoma
- (2008) Daniel G. Haller et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer
- (2008) Jim Cassidy et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials
- (2008) Emmanuel Mitry et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutations ofKRASandBRAFin Primary and Matched Metastatic Sites of Colorectal Cancer
- (2008) Salvatore Artale et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer
- (2008) Brigit Gruenberger et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- (2008) Leonard B. Saltz et al. JOURNAL OF CLINICAL ONCOLOGY
- Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer
- (2008) Steven J. Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
- (2008) Alberto F. Sobrero et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- Complete Cytoreductive Surgery Plus Intraperitoneal Chemohyperthermia With Oxaliplatin for Peritoneal Carcinomatosis of Colorectal Origin
- (2008) Dominique Elias et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
- (2008) Carsten Bokemeyer et al. JOURNAL OF CLINICAL ONCOLOGY
- Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
- (2008) Bernard Nordlinger et al. LANCET
- Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study)
- (2008) Riccardo Lencioni et al. LANCET ONCOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
- High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice
- (2008) D. Santini et al. ONCOLOGIST
- Bevacizumab Improves the Overall and Progression-Free Survival of Patients with Metastatic Colorectal Cancer Treated with 5-Fluorouracil-Based Regimens Irrespective of Baseline Risk
- (2008) Fairooz Kabbinavar et al. ONCOLOGY
- CT-Guided Interstitial Brachytherapy of Primary and Secondary Lung Malignancies
- (2008) Nils Peters et al. STRAHLENTHERAPIE UND ONKOLOGIE
- KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program
- (2008) J. H. J. M. van Krieken et al. VIRCHOWS ARCHIV
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started